Mahzi Therapeutics
Develops gene therapies and other treatments for rare genetic neurodevelopmental disorders.
Raising now
OpenRaising on Wefunder ↗
- As of Nov 1, 2026
- $349,425 raised from 144 investors
- Target, as of Nov 1, 2026
- $1,200,000
- Maximum, as of Nov 1, 2026
- $1,200,000
- Closes
- Dec 31, 2026
As Wefunder reports them, as of Nov 1, 2026
- Security
- equity
- Share class
- preferred
- Share price
- $3.47
- Pre money valuation
- $87,900,000
- Exemption
- Reg CF
- Minimum
- $250
From the SEC Form C
- Security (as filed)
- Preferred Stock
- Price
- $3.47
- Filed
- Jun 17, 2026
- Incorporated in
- DE
- Employees
- 14
- Revenue, last fiscal year
- $0
- Net income, last fiscal year
- -$18,656,306
EarlySignals' view, not the portal's
Our potential score, six-dimension radar and research are for members.
Figures are the portal's own, as of the date shown. Not investment advice; EarlySignals takes no payment from issuers or portals.